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LETTERS TO THE EDITOR
Associating Mitochondrial DNA Variation with
Complex Traits
To the Editor:
We read with great interest the recent paper by Saxena
and colleagues describing the “comprehensive association
testing of common mitochondrial DNA [mtDNA] varia-
tion in metabolic disease.”1 We strongly support the use
of large cohorts of carefully phenotyped cases and controls
in studies of this type, large cohorts being essential to
provide adequate power to detect small or moderate as-
sociations between mtDNA sequence variants and dis-
ease.2 We do, however, have concerns that the study de-
scribed by Saxena et al. is neither sufficiently accurate
nor sufficiently comprehensive for exploring all possible
mechanisms of disease association with common genetic
variants of mtDNA. We therefore urge caution when ap-
plying their approach to other disease states, because it is
not well grounded in the fundamental aspects of mtDNA
phylogenetics. As a result, their approach may lead to spu-
rious associations, as well as to false negative results.
Mitochondrial DNA is inherited strictly down the ma-
ternal line and therefore undergoes negligible intermo-
lecular recombination, and the signature of recombina-
tion has not been detected at the population level.3,4
Mutations acquired throughout human history have sub-
divided the human population into a number of discrete
clades or haplogroups.5 The major haplogroups have been
identified by a search for common genetic variants in the
population, initially through the use of restriction site
analysis and subsequently through direct sequencing of
both coding and noncoding regions of mtDNA.6 In con-
structing the most parsimonious phylogenetic structure
of human mtDNA evolution, it has become clear that
many substitutions have arisen more than once on dif-
ferent parts of the phylogenetic tree (i.e., homoplasies; see
table 2 in the work of Herrnstadt et al.7 for the most com-
plete list). Homoplasy adds complexity to the population
structure of mtDNA, and it is a serious confounding phe-
nomenon in the association approach used by Saxena et
al.
Saxena and colleagues used publicly available human
mtDNA coding-sequence data sets to identify mtDNA
polymorphisms that occur at a frequency of 11% in the
European population. To derive this key information, the
authors state that they used only sequences of European
origin to compile their list of polymorphisms. Thus, they
report that they used 536 sequences from the MitoKor
data set released by Herrnstadt et al.7 However, this data
set contained a total of 560 sequences, of which 56 were
African, 69 Asian, and only 435 European. On the basis
of their report, it appears that Saxena et al. included at
least 101 non-European sequences in their core data set,
some ∼8% of the total. The inclusion of sequences from
non-European subjects could have resulted in the iden-
tification of non-European SNPs in their initial data set or
in the exclusion of specific European variants, because, in
their set of 536 sequences, some rare European markers
fell below the 1% threshold for inclusion. As an example,
site 13105 is most often associated with African lineages,
and, in the MitoKor data, it is present in 23 of 56 sequences
of African origin but in only 3 of 435 sequences of Eu-
ropean origin. As a result, this site should not have been
used in the analysis of Saxena et al.
Even the strict use of European sequences is not without
problems. Of the GenBank mtDNA sequences used by Sax-
ena et al., 192 were of Finnish origin. It is now recognized
that some mtDNA clades are considerably overrepresented
in the Finnish phylogeny, presumably because of a recent
founder event.8,9 For example, site m.4928 is absent in the
435 MitoKor European mtDNA sequences but is reported
in 13 Finns. In a similar fashion, site 5495 is seen in only
2 of 435 MitoKor sequences but was observed in 23 Finns.9
As a result, there is another reason to doubt that the
authors were able to analyze a representative set of
mtDNA SNPs. At best, it appears that their approach is
reliable only for robust disease associations with common
markers.
Perhaps more importantly, although many of the U.S.
and U.K. samples from the MitoKor data set were from
the population controls, Herrnstadt et al. explicitly noted
that the data set also included mtDNA sequences from
patients with various disorders. In fact, the MitoKor set of
435 sequences of European origin included patients with
type 2 diabetes ( [MIM 125853]), with Alzheimernp 42
disease ( [MIM 104300]), and with Parkinson dis-np 60
ease ( [MIM 168600]), thereby accounting for atnp 37
least 11% of the core data set. This is not a problem if the
sequences are being used simply to draw general conclu-
sions about the pattern of mtDNA evolution in the pop-
ulation. However, given the reported association between
these diseases and mtDNA sequence variants,10–13 the use
of these sequences potentially alters the spectrum of poly-
morphic change identified in the first phase of the study
by Saxena et al. and subsequently influencing the final
list of “tag” SNPs.
Saxena et al. used mathematical methods designed to
measure linkage disequilibrium to identify SNPs that tag
common mtDNA haplotypes as a way to identify haplo-
group clusters. In a comparison of the haplotype tags
described by Saxena et al. with a phylogenetic analysis
of European mtDNA sequences, a number of patterns
emerge. The approach reliably detects some common2r
haplogroup-defining polymorphisms but—and this is an
important point—not others. For example, mtDNA hap-
logroup T is reliably tagged by two tags, m.12633 and
m.11812, that capture site m.8697 shared by all haplo-
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group T sequences (shown in blue in fig. 1). However, their
technique also identifies common homoplasies, which
can account for up to 25% of substitutions in some data
sets.9 As one example, in the MitoKor set of 560 sequences,
497 haplogroup-associated polymorphisms were identi-
fied, but 174 (35%) of these were associated with two or
more haplogroups. The majority of established mtDNA
haplotypes are defined by a combination of SNPs, and, by
their very definition, a single homoplasy cannot be used
to reliably “tag” a single mtDNA haplotype. The approach
of Saxena et al. leads to the association analysis of poly-
phyletic groups (e.g., as shown in fig. 1, m.709 is found
independently on haplogroups U, K, T, and W). On the
basis of the phylogeny shown in the figure, at least 53%
of the tag SNPs identified by Saxena et al. are associated
not with a single mtDNA haplotype but with two or more.
Thus, their comparison of the frequencies of a common
homoplasy in cases and controls is fraught with difficulty.
If one of the distal branches of the phylogenetic tree does
harbor a functionally relevant disease-associated poly-
morphism, that association with the tagging homoplasic
marker will be “diluted” by the co-occurrence of the same
mtDNA substitution on other, nonassociated clades. An
example is shown in red in figure 1, site m.12795 and
m.709 capture m.5046 of haplogroup W. However, be-
cause of the occurrence of m.709 at multiple places in the
phylogeny, many other unrelated sequences are also cap-
tured. On the other hand, if the homoplasy itself con-
tributes to pathogenicity, then it might be possible to use
the approach developed by Saxena et al. for the identifi-
cation of a disease association. However, the reported aim
of this approach was to identify tag SNPs and not the
functional variants themselves.
Another problem with the approach of Saxena et al. is
that, by ignoring what is known about mtDNA evolu-
tionary history, they tested a number of sites that were
providing the same information on association. For ex-
ample, both m.11674 and m.12414 “tag” mtDNA hap-
logroup W (fig. 1). On the basis of an updated reduced
median network analysis of the MitoKor data set, 12 (19%)
of the 64 tag SNPs studied by Saxena et al. occur in exactly
the same place on the phylogeny as other tag SNPs (green
boxes in fig. 1). Thus, their approach is inefficient, because
of the increased superfluous genotyping, tagging the same
haplotype on more than one occasion. This is an instance
where less can be more. That is, by using fewer SNPs—but
ones that are specifically chosen on the basis of knowledge
of mtDNA phylogeny—it is possible to cover all major
clades of mtDNA. This approach would reduce the number
of statistical tests being performed and thus would in-
crease the power of the study, potentially revealing a sig-
nificant and biologically relevant association.
The conventional first step in studying the association
between mtDNA and complex disease involves the se-
quential genotyping of specific SNPs that, in European
populations, define the major European haplogroups. The
results are interpreted in a stepwise manner, with reference
to the phylogenetic tree, to prevent misinterpretations
due to the occurrence of homoplasies. For example, the
presence of m.4216 defines the JT cluster, which is sepa-
rated into J and T by m.13708. However, genotyping
m.13708 on its own does not define J, because, among
European mtDNAs, the same substitution occurs on a sub-
group of haplogroup K and X.
By its very nature, the approach of Saxena et al. iden-
tifies some common haplogroup markers, but how much
additional “tagging” information was acquired by their 64
SNPs? After removal of the nonunique sites ( ),np 35
which occur more than once on the phylogeny and thus
do not tag a specific haplotype, followed by removal of
the unique haplogroup markers ( ), 24 unique sitesnp 5
remain (38% of the original total). On the basis of the
MitoKor data set, these 24 SNPs tag only 142 of 435 Eu-
ropean sequences and, by extrapolation, only 33% of the
European population (shown in shaded yellow in fig. 1).
The 64 SNPs described by Saxena et al. can be used to
test two hypotheses in part: (1) association of a disease
with deep-rooted, ancient mtDNA polymorphisms (an as-
sociation occurs either because the specific variant has di-
rect functional consequences or because it tags a clade
containing functionally relevant variants); and (2) asso-
ciation of the disease with ancestrally young genetic var-
iants that are present on multiple different haplogroup
backgrounds. Of the 24 unique sites that do not tag major
haplogroups, only 6 could have direct functional conse-
quences (affecting tRNA genes, rRNA genes, or the protein
sequence), with the majority ( ) being synonymousnp 15
changes within structural genes. Interpreting the results
of the analysis is therefore ambiguous—whether the out-
come is positive or negative. The approach of Saxena et
al. seems beautifully simple, with both statistical signifi-
cance and power calculated by simulation and random
permutation of the data. However, the examples presented
here demonstrate the complexity and limitations of the
data structure and show that it becomes very difficult to
test a disease association without accounting for phylo-
genetic history. That is, their statistical tests are sound, but
they are applied to flawed data in this instance.
Although we acknowledge that their approach will de-
tect a robust disease association, little comfort can be
taken because such associations are detected by other ap-
proaches. More importantly, we are learning that the re-
verse seems to be case for disease associations. That is,
there is accumulating evidence that such associations will
be weak and/or genetically complex.
In terms of what is emerging from other analyses, it
must be noted that the approach of Saxena et al. does not
test the equally plausible hypothesis that multiple mtDNA
variants interact and subtly compromise respiratory chain
function. This type of association is not without prece-
dent, because suppressor mutations have been described
in patients with mitochondrial disorders and possibly
have occurred throughout mtDNA evolution.14 In terms
of a specific example, an association has been found be-
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Figure 1. Revised and updated reduced median network analysis of European mtDNA sequences from the MitoKor data set, adapted
from the work of Herrnstadt et al.7 A reticulation at the haplogroups W, I, and X has been resolved. An example of haplogroup H4 has
been added. Tag SNPs described in table 4 of Saxena et al.1 are shown in bold italics (not all are present on the network). Underlined
sites are homoplasies in the 435 European sequences of the MitoKor data set. In a larger data set, it is likely that the number of
homoplasies would be greater; thus, the data set used by Saxena et al. will have fewer unique sites. Blue, An example of good tagging
of a cluster of related mtDNA sequences. Red, An example of a tag SNP that is a common homoplasy, present at many different sites
on the phylogeny. Green, An example of two SNPs that uniquely occur at exactly the same point on the phylogeny and thus provide
the same information regarding that particular clade. Green boxes, Other examples of SNPs that occur at the same point on the phylogeny.
Yellow bubbles, The areas of the phylogeny captured by the unique sites of Saxena et al. The total number of sequences captured (142)
is 66 greater than shown on the network, which does not show all the H sequences in the data set of 435 European mtDNA sequences
(because of space limitations).
tween longevity and a combination of three common
polymorphisms m.150T, m.489C, and m.10398G.16 Such
a disease process fits with the basic biology of the mito-
chondrial electron-transfer chain, in which all of the genes
encoded by the mitochondrial genome contribute to the
same basic biochemical process of oxidative phosphoryl-
ation.15 Mitochondrial structure and function are guided
by the interaction of hundreds of nuclear- and mitochon-
drially-encoded subunits. It will be a major challenge to
test the hypothesis that multiple mtDNA variants interact
to alter disease risk—but without testing this hypothesis,
no approach can be said to be “comprehensive.”
Finally, mitochondrial disorders are metabolic diseases,
affecting the final common pathway of energy metabo-
lism. Leber hereditary optic neuropathy (LHON [MIM
535000]) is the most common mtDNA disease, and 195%
of cases are caused by one of three point mutations of
mtDNA affecting genes that code for complex I subunits
of the respiratory chain: m.3460GrA, m.11778GrA, and
m.14484TrC.17 These mutations have arisen many times
over human history, and they are associated with a met-
abolic defect of respiratory chain complex I activity. In-
triguingly, only m.11778GrA and m.14484TrC prefer-
entially occur on a specific mtDNA haplogroup back-
ground (J).18,19 The most likely explanation for these re-
sults is that the penetrance (or expressivity) of these path-
ogenic mutations is modified by the mitochondrial ge-
netic “background.” Recent work suggests that specific
subhaplogroups (J1c and J2b) are responsible for this as-
sociation, possibly through polymorphic variation in the
mtDNA cytochrome b gene.20 Iranian pedigrees affected
by LHON do not show the same the association with hap-
logroup J.22 However, the conspicuous absence of both J1c
and J2b from the Iranian population probably explains
this observation, illustrating the important point that a
clear knowledge of the local population genetic structure,
derived from phylogenetics, informs our understanding
of relevant disease associations (or the lack thereof).20 Al-
though there is evidence that genetic variation of mtDNA
is associated with some mitochondrial disorders, this is
not always the case.21
An alternative approach to that of Saxena et al., as men-
tioned above, is to use our knowledge of mtDNA popu-
lation structure to reduce the number of redundant sta-
tistical tests and thus to increase the power of the study.
For example, one such hypothesis-driven approach would
involve testing for an association between nonsynony-
mous mtDNA homoplasies and disease on different
mtDNA haplogroup backgrounds. This hierarchical strat-
egy would provide a means of independently testing a
disease association multiple times within the same data
set. Careful selection of specific SNPs on the basis of prior
knowledge of their evolutionary conservation and likely
biochemical effect might also reduce the number of sta-
tistical tests being performed. We believe that such hy-
pothesis-driven approaches are less likely to identify a
false-positive association. They will also maximize the po-
tential of a given sample size, revealing associations that
are biologically plausible and that may not be apparent
after less-discriminate genotyping followed by a correc-
tion for multiple significance testing or by a simulation-
based significance test not reflecting the true structure of
genome evolution. In the end, we should expect that a
“one size fits all” approach is simply not optimal and that
analysis of large data sets with multiple hypothesis-based
tests will be necessary.
JOANNA L. ELSON, KARI MAJAMAA, NEIL HOWELL,
AND PATRICK F. CHINNERY
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for Alzheimer disease, LHON, Parkinson
disease, and type 2 diabetes)
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Reply to Elson et al.
To the Editor:
We recently reported an association study of common
mtDNA variation with risk of type 2 diabetes and metabolic
traits.1 We tested a simple model with few assumptions: that
each common DNA sequence variant might, irrespective of
its place in the mtDNA phylogeny, be associated with dis-
ease. Although Elson et al.2 agree that our “approach will
detect a robust disease association,” they have three con-
cerns: (i) that the catalogue of common variation is not
representative of European mtDNAs, (ii) that our tag SNPs
do not adequately capture mtDNA haplogroups, and (iii)
that we failed to consider epistasis. We believe these views
to be misinterpretations of our article, as well as a reflection
of a difference in philosophy on limiting associationstudies
on the basis of prior assumptions.
We developed a catalogue of common mtDNA variation
on the basis of publicly available mtDNA sequences. Per-
haps we were insufficiently precise in the text, as Elson et
al. misinterpret which samples were used. In the European
alignment, we studied 928 mtDNAs of only European or-
igin: 429 from MitoKor, 240 from the Armed Forces Insti-
tute of Pathology, 192 from Finland, and 67 from smaller
studies. (Although we used 536 MitoKor sequences for
